 | • レポートコード：MRC23Q35831 • 出版社/出版日：QYResearch / 2023年3月 • レポート形態：英文、PDF、98ページ • 納品方法：Eメール（2-3日） • 産業分類：医療 |
| Single User | ￥435,000 (USD2,900) | ▷ お問い合わせ |
| Enterprise License | ￥870,000 (USD5,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本調査レポートは世界の血漿分画技術市場について調査・分析し、世界の血漿分画技術市場概要、市場トレンド、主要企業別競争状況、タイプ別セグメント分析（アルブミン、免疫グロブリン、凝固因子、その他）、用途別セグメント分析（病院、薬局、その他）、地域別市場規模、主要企業のプロファイルなどに関する情報を掲載しています。主要企業としては、Takeda、CSL、Grifols、Octapharma、Kedrion、LFB Group、Biotest、BPL、RAAS、CBPO、Hualan Bio、Tiantan Bio、Shuanglin Bio、Boya Bio、Yuanda Shuyang、Weiguang Bio、Nanyue Bio、KM Biologicsなどが含まれています。世界の血漿分画技術市場は、2022年にXXX米ドル、2029年にはXXX米ドルに達すると予測され、予測期間の年平均成長率はXXX％です。COVID-19とロシア・ウクライナ戦争の影響は、血漿分画技術市場規模を推定する際に考慮しました。本レポートは、血漿分画技術の世界市場を定量的・定性的な分析により包括的に提示し、読者がビジネス/成長戦略を策定し、市場競争状況を把握し、現在の市場における自社のポジションを分析し、血漿分画技術に関するビジネス上の意思決定に役立てることを目的としています。 ・血漿分画技術市場の概要 - 血漿分画技術のタイプ別セグメント - 世界の血漿分画技術市場規模：タイプ別分析（アルブミン、免疫グロブリン、凝固因子、その他） - 血漿分画技術の用途別セグメント - 世界の血漿分画技術市場規模：用途別分析（病院、薬局、その他） - 世界の血漿分画技術市場規模予測（2018年-2029年） ・血漿分画技術市場の成長トレンド - 血漿分画技術の地域別市場規模（2018年-2029年） - 血漿分画技術市場ダイナミクス - 血漿分画技術の業界動向 - 血漿分画技術市場の成長ドライバ、課題、阻害要因 ・主要企業別競争状況 - 企業別市場シェア - 世界の主要企業、業界ランキング分析 - 市場への参入、M＆A動向 ・タイプ別セグメント：アルブミン、免疫グロブリン、凝固因子、その他 - 世界の血漿分画技術のタイプ別市場規模（2018年-2023年） - 世界の血漿分画技術のタイプ別市場規模（2024年-2029年） ・用途別セグメント：病院、薬局、その他 - 世界の血漿分画技術の用途別市場規模（2018年-2023年） - 世界の血漿分画技術の用途別市場規模（2024年-2029年） ・血漿分画技術の地域別市場規模 - 北米の血漿分画技術市場規模（2018年-2029年） - アメリカの血漿分画技術市場規模（2018年-2029年） - ヨーロッパの血漿分画技術市場規模（2018年-2029年） - アジア太平洋の血漿分画技術市場規模（2018年-2029年） - 中国の血漿分画技術市場規模（2018年-2029年） - 日本の血漿分画技術市場規模（2018年-2029年） - 韓国の血漿分画技術市場規模（2018年-2029年） - インドの血漿分画技術市場規模（2018年-2029年） - オーストラリアの血漿分画技術市場規模（2018年-2029年） - 中南米の血漿分画技術市場規模（2018年-2029年） - 中東・アフリカの血漿分画技術市場規模（2018年-2029年） ・主要企業のプロファイル：企業情報、事業概要、売上、動向 Takeda、CSL、Grifols、Octapharma、Kedrion、LFB Group、Biotest、BPL、RAAS、CBPO、Hualan Bio、Tiantan Bio、Shuanglin Bio、Boya Bio、Yuanda Shuyang、Weiguang Bio、Nanyue Bio、KM Biologics ・アナリストの観点/結論 ・調査方法とデータソース |
Highlights
The global Blood Plasma Fractionation Technology market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
North American market for Blood Plasma Fractionation Technology is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
Asia-Pacific market for Blood Plasma Fractionation Technology is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The global market for Blood Plasma Fractionation Technology in Hospital is estimated to increase from $ million in 2023 to $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The key global companies of Blood Plasma Fractionation Technology include Takeda, CSL, Grifols, Octapharma, Kedrion, LFB Group, Biotest, BPL and RAAS, etc. In 2022, the world’s top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Blood Plasma Fractionation Technology, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Blood Plasma Fractionation Technology.
The Blood Plasma Fractionation Technology market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Blood Plasma Fractionation Technology market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Blood Plasma Fractionation Technology companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.
By Company
Takeda
CSL
Grifols
Octapharma
Kedrion
LFB Group
Biotest
BPL
RAAS
CBPO
Hualan Bio
Tiantan Bio
Shuanglin Bio
Boya Bio
Yuanda Shuyang
Weiguang Bio
Nanyue Bio
KM Biologics
Segment by Type
Albumin
Immune Globulin
Coagulation Factor
Others
Segment by Application
Hospital
Retail Pharmacy
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Blood Plasma Fractionation Technology companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Blood Plasma Fractionation Technology Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Albumin
1.2.3 Immune Globulin
1.2.4 Coagulation Factor
1.2.5 Others
1.3 Market by Application
1.3.1 Global Blood Plasma Fractionation Technology Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Hospital
1.3.3 Retail Pharmacy
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Blood Plasma Fractionation Technology Market Perspective (2018-2029)
2.2 Blood Plasma Fractionation Technology Growth Trends by Region
2.2.1 Global Blood Plasma Fractionation Technology Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Blood Plasma Fractionation Technology Historic Market Size by Region (2018-2023)
2.2.3 Blood Plasma Fractionation Technology Forecasted Market Size by Region (2024-2029)
2.3 Blood Plasma Fractionation Technology Market Dynamics
2.3.1 Blood Plasma Fractionation Technology Industry Trends
2.3.2 Blood Plasma Fractionation Technology Market Drivers
2.3.3 Blood Plasma Fractionation Technology Market Challenges
2.3.4 Blood Plasma Fractionation Technology Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Blood Plasma Fractionation Technology Players by Revenue
3.1.1 Global Top Blood Plasma Fractionation Technology Players by Revenue (2018-2023)
3.1.2 Global Blood Plasma Fractionation Technology Revenue Market Share by Players (2018-2023)
3.2 Global Blood Plasma Fractionation Technology Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Blood Plasma Fractionation Technology Revenue
3.4 Global Blood Plasma Fractionation Technology Market Concentration Ratio
3.4.1 Global Blood Plasma Fractionation Technology Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Blood Plasma Fractionation Technology Revenue in 2022
3.5 Blood Plasma Fractionation Technology Key Players Head office and Area Served
3.6 Key Players Blood Plasma Fractionation Technology Product Solution and Service
3.7 Date of Enter into Blood Plasma Fractionation Technology Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Blood Plasma Fractionation Technology Breakdown Data by Type
4.1 Global Blood Plasma Fractionation Technology Historic Market Size by Type (2018-2023)
4.2 Global Blood Plasma Fractionation Technology Forecasted Market Size by Type (2024-2029)
5 Blood Plasma Fractionation Technology Breakdown Data by Application
5.1 Global Blood Plasma Fractionation Technology Historic Market Size by Application (2018-2023)
5.2 Global Blood Plasma Fractionation Technology Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Blood Plasma Fractionation Technology Market Size (2018-2029)
6.2 North America Blood Plasma Fractionation Technology Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Blood Plasma Fractionation Technology Market Size by Country (2018-2023)
6.4 North America Blood Plasma Fractionation Technology Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Blood Plasma Fractionation Technology Market Size (2018-2029)
7.2 Europe Blood Plasma Fractionation Technology Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Blood Plasma Fractionation Technology Market Size by Country (2018-2023)
7.4 Europe Blood Plasma Fractionation Technology Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Blood Plasma Fractionation Technology Market Size (2018-2029)
8.2 Asia-Pacific Blood Plasma Fractionation Technology Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Blood Plasma Fractionation Technology Market Size by Region (2018-2023)
8.4 Asia-Pacific Blood Plasma Fractionation Technology Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Blood Plasma Fractionation Technology Market Size (2018-2029)
9.2 Latin America Blood Plasma Fractionation Technology Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Blood Plasma Fractionation Technology Market Size by Country (2018-2023)
9.4 Latin America Blood Plasma Fractionation Technology Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Blood Plasma Fractionation Technology Market Size (2018-2029)
10.2 Middle East & Africa Blood Plasma Fractionation Technology Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Blood Plasma Fractionation Technology Market Size by Country (2018-2023)
10.4 Middle East & Africa Blood Plasma Fractionation Technology Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Takeda
11.1.1 Takeda Company Detail
11.1.2 Takeda Business Overview
11.1.3 Takeda Blood Plasma Fractionation Technology Introduction
11.1.4 Takeda Revenue in Blood Plasma Fractionation Technology Business (2018-2023)
11.1.5 Takeda Recent Development
11.2 CSL
11.2.1 CSL Company Detail
11.2.2 CSL Business Overview
11.2.3 CSL Blood Plasma Fractionation Technology Introduction
11.2.4 CSL Revenue in Blood Plasma Fractionation Technology Business (2018-2023)
11.2.5 CSL Recent Development
11.3 Grifols
11.3.1 Grifols Company Detail
11.3.2 Grifols Business Overview
11.3.3 Grifols Blood Plasma Fractionation Technology Introduction
11.3.4 Grifols Revenue in Blood Plasma Fractionation Technology Business (2018-2023)
11.3.5 Grifols Recent Development
11.4 Octapharma
11.4.1 Octapharma Company Detail
11.4.2 Octapharma Business Overview
11.4.3 Octapharma Blood Plasma Fractionation Technology Introduction
11.4.4 Octapharma Revenue in Blood Plasma Fractionation Technology Business (2018-2023)
11.4.5 Octapharma Recent Development
11.5 Kedrion
11.5.1 Kedrion Company Detail
11.5.2 Kedrion Business Overview
11.5.3 Kedrion Blood Plasma Fractionation Technology Introduction
11.5.4 Kedrion Revenue in Blood Plasma Fractionation Technology Business (2018-2023)
11.5.5 Kedrion Recent Development
11.6 LFB Group
11.6.1 LFB Group Company Detail
11.6.2 LFB Group Business Overview
11.6.3 LFB Group Blood Plasma Fractionation Technology Introduction
11.6.4 LFB Group Revenue in Blood Plasma Fractionation Technology Business (2018-2023)
11.6.5 LFB Group Recent Development
11.7 Biotest
11.7.1 Biotest Company Detail
11.7.2 Biotest Business Overview
11.7.3 Biotest Blood Plasma Fractionation Technology Introduction
11.7.4 Biotest Revenue in Blood Plasma Fractionation Technology Business (2018-2023)
11.7.5 Biotest Recent Development
11.8 BPL
11.8.1 BPL Company Detail
11.8.2 BPL Business Overview
11.8.3 BPL Blood Plasma Fractionation Technology Introduction
11.8.4 BPL Revenue in Blood Plasma Fractionation Technology Business (2018-2023)
11.8.5 BPL Recent Development
11.9 RAAS
11.9.1 RAAS Company Detail
11.9.2 RAAS Business Overview
11.9.3 RAAS Blood Plasma Fractionation Technology Introduction
11.9.4 RAAS Revenue in Blood Plasma Fractionation Technology Business (2018-2023)
11.9.5 RAAS Recent Development
11.10 CBPO
11.10.1 CBPO Company Detail
11.10.2 CBPO Business Overview
11.10.3 CBPO Blood Plasma Fractionation Technology Introduction
11.10.4 CBPO Revenue in Blood Plasma Fractionation Technology Business (2018-2023)
11.10.5 CBPO Recent Development
11.11 Hualan Bio
11.11.1 Hualan Bio Company Detail
11.11.2 Hualan Bio Business Overview
11.11.3 Hualan Bio Blood Plasma Fractionation Technology Introduction
11.11.4 Hualan Bio Revenue in Blood Plasma Fractionation Technology Business (2018-2023)
11.11.5 Hualan Bio Recent Development
11.12 Tiantan Bio
11.12.1 Tiantan Bio Company Detail
11.12.2 Tiantan Bio Business Overview
11.12.3 Tiantan Bio Blood Plasma Fractionation Technology Introduction
11.12.4 Tiantan Bio Revenue in Blood Plasma Fractionation Technology Business (2018-2023)
11.12.5 Tiantan Bio Recent Development
11.13 Shuanglin Bio
11.13.1 Shuanglin Bio Company Detail
11.13.2 Shuanglin Bio Business Overview
11.13.3 Shuanglin Bio Blood Plasma Fractionation Technology Introduction
11.13.4 Shuanglin Bio Revenue in Blood Plasma Fractionation Technology Business (2018-2023)
11.13.5 Shuanglin Bio Recent Development
11.14 Boya Bio
11.14.1 Boya Bio Company Detail
11.14.2 Boya Bio Business Overview
11.14.3 Boya Bio Blood Plasma Fractionation Technology Introduction
11.14.4 Boya Bio Revenue in Blood Plasma Fractionation Technology Business (2018-2023)
11.14.5 Boya Bio Recent Development
11.15 Yuanda Shuyang
11.15.1 Yuanda Shuyang Company Detail
11.15.2 Yuanda Shuyang Business Overview
11.15.3 Yuanda Shuyang Blood Plasma Fractionation Technology Introduction
11.15.4 Yuanda Shuyang Revenue in Blood Plasma Fractionation Technology Business (2018-2023)
11.15.5 Yuanda Shuyang Recent Development
11.16 Weiguang Bio
11.16.1 Weiguang Bio Company Detail
11.16.2 Weiguang Bio Business Overview
11.16.3 Weiguang Bio Blood Plasma Fractionation Technology Introduction
11.16.4 Weiguang Bio Revenue in Blood Plasma Fractionation Technology Business (2018-2023)
11.16.5 Weiguang Bio Recent Development
11.17 Nanyue Bio
11.17.1 Nanyue Bio Company Detail
11.17.2 Nanyue Bio Business Overview
11.17.3 Nanyue Bio Blood Plasma Fractionation Technology Introduction
11.17.4 Nanyue Bio Revenue in Blood Plasma Fractionation Technology Business (2018-2023)
11.17.5 Nanyue Bio Recent Development
11.18 KM Biologics
11.18.1 KM Biologics Company Detail
11.18.2 KM Biologics Business Overview
11.18.3 KM Biologics Blood Plasma Fractionation Technology Introduction
11.18.4 KM Biologics Revenue in Blood Plasma Fractionation Technology Business (2018-2023)
11.18.5 KM Biologics Recent Development
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details